Status:
COMPLETED
Lobaplation or Cisplatin in Adjuvant Chemotherapy for Esophageal Carcinoma
Lead Sponsor:
Henan Cancer Hospital
Conditions:
Esophageal Cancer
Eligibility:
All Genders
Phase:
PHASE4
Brief Summary
The multicenter real-world and propensity score matching comparative study was designed to explore the toxicity and effectiveness of Lobaplation or Cisplatin based adjuvant chemotherapy in esophageal ...
Detailed Description
This trial is a multicenter real-world retrospective comparative study. The patients with thoracic esophageal squamous cell carcinoma, esophagectomy and adjuvant chemotherapy(Cisplatin plus Docetaxel ...
Eligibility Criteria
Inclusion
- i) thoracic ESCC stage II to III; ii) without any preoperation treatment for ESCC; iii) underwent R0 resection; iv) received ajuvant chemotherapy of Cisplatin plus Docetaxel or Lobaplatin plus Docetaxel.
Exclusion
- i) with ajuvant radiotherapy/chemoradiotherapy; ii) history of other type of cancer iii) without completed clinical, pathological and follow up data.
Key Trial Info
Start Date :
January 31 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 21 2018
Estimated Enrollment :
733 Patients enrolled
Trial Details
Trial ID
NCT03413436
Start Date
January 31 2018
End Date
February 21 2018
Last Update
August 28 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university
Zhengzhou, Henan, China, 450008